""Starting next year, American drug prices will come down fast and furious and will soon be the lowest in the developed world," President Donald Trump claimed Friday as the White House announced agreements with nine pharmaceutical manufacturers. The administration struck most favored nation (MFN) pricing deals with Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. The president - who has launched the related TrumpRx.gov - previously reached agreements with AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, and Pfizer."
""When 47% of Americans are concerned they won't be able to afford a healthcare cost next year, steps to reduce drug prices for patients are welcomed, especially by patients who rely on one of the overpriced essential medicines named in today's announcement," said Merith Basey, CEO of Patients for Affordable Drugs Now, in a statement."
The administration announced most favored nation (MFN) pricing agreements with numerous major pharmaceutical companies and launched TrumpRx.gov to publicize the deals. Agreements include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi, alongside earlier deals with AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, and Pfizer. The White House noted MFN deals cover 14 of the 17 biggest global drugmakers; AbbVie, Johnson & Johnson, and Regeneron were not included but could be added later. Critics cautioned that voluntary deals may be insufficient as policy moves could remove millions from Medicaid and raise ACA premiums, increasing uninsured risk.
#prescription-drug-pricing #most-favored-nation-mfn #pharmaceutical-agreements #medicaid-and-aca-policy
Read at Truthout
Unable to calculate read time
Collection
[
|
...
]